Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Pierotti

Orthopaedic Surgery Dubuque, IA Medical Doctor

NPI 1154328029 CMS profile 6382

1500 Delhi St, Ste 4200, Dubuque, IA 52001

Open in the dashboard

General payments

$1,228

34 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Pierotti of Dubuque, IA is reported in the CMS Open Payments database as having received $1,228 across 34 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $382 9
2024 General $72 3
2023 General $132 5
2022 General $143 3
2021 General $175 5
2020 General $271 6
2019 General $53 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Pierotti
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Stephen Pierotti were reported at $382. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Stephen Pierotti Orthopaedic Surgery median Middle half National median
2019 $53 $644 $140–$2,844 $163
2020 $271 $312 $75–$1,860 $114
2021 $175 $520 $117–$2,495 $132
2022 $143 $598 $128–$2,731 $149
2023 $132 $461 $128–$2,264 $160
2024 $72 $497 $134–$2,475 $164
2025 $382 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Sales Inc. $691 16 payments
  2. Stryker Corporation $231 6 payments
  3. Wardlow Enterprises $91 1 payment
  4. Vertex Pharmaceuticals Incorporated $54 3 payments
  5. Smith+Nephew, Inc. $32 1 payment
  6. Ferring Pharmaceuticals Inc. $27 1 payment
  7. Pacira Pharmaceuticals Incorporated $22 1 payment
  8. Bioventus LLC $21 1 payment
  9. Endo Pharmaceuticals Inc. $15 1 payment
  10. Medical Device Business Services, Inc. $15 1 payment
  11. Other $28 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,228 34 payments
Products named General payments · program years 2019–2025
  1. Velys $106 1 payment
  2. VELYS Hip Navigation $91 1 payment
  3. Kincise Surgical Automated System $91 1 payment
  4. MAKO $88 1 payment
  5. Fibulink $63 2 payments
  6. ALPHAVENT $61 2 payments
  7. INSPACE $56 2 payments
  8. JOURNAVX $54 3 payments
  9. VA-LCP $43 2 payments
  10. ORTHOVISC $42 3 payments
  11. Other $530 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,148

Median for Orthopedic Surgery: 203

Drug cost

$6,730

Median for Orthopedic Surgery: $1,433

Branded share of claims

17.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 68 $1,780
Doxycycline Hyclate Generic 12 $1,246
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 142 $774
Cephalexin Generic 398 $761
Tramadol Hcl Generic 185 $524
Nabumetone Generic 11 $234
Ondansetron Odt Ondansetron Brand 18 $209
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 38 $205
Pantoprazole Sodium Generic 31 $188
Meloxicam Generic 71 $186

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$152,558

Of which drugs: $24,054

Medicare patients

444

Average age 74

Services billed

4,143

268 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 66%
Diabetes 27%
Depression 22%
Chronic kidney disease 20%
Ischemic heart disease 16%
Heart failure 14%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg J7322 Office 20 1,344 $17,835
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 179 1,139 $761

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $7
$8 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $7
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

34 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record